AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04944836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator Cuff Repair
Description: The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
Study NCT04944836 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rotator Cuff Repair
Description: The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
Study NCT05700279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate Ganglion Block
Description: Stellate Ganglion Block (SGB) procedure involves an injection of a local anesthetic (0.5% ropivacaine) around the stellate ganglion (a bundle of nerves located at the base of the neck) to block the transmission of pain signals. The SGB injection is administered by an anesthesiologist.
Study NCT05700279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy (CPT) is a form of trauma-based talk therapy that will be conducted by clinical therapists. CPT can help people identify and challenge unhelpful trauma-related beliefs about themselves, others, and the world.
Study NCT05797467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy regimens
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
Study NCT05797467 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: FOLFOX chemotherapy regimens
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
Study NCT05797467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Targeted therapy regimens are recommended based on gene testing results. For colorectal cancer patients with KRAS/NRAS/BRAF gene mutations, it is recommended to use Bevacizumab in combination with chemotherapy. For right-sided colon cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Bevacizumab. For left-sided colon and rectal cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Cetuximab.When using targeted therapy in combination with chemotherapy, the treatment course should be synchronized with chemotherapy (Bev 5mg/kg iv d1 or Cet 500mg/m2 iv d1).
Study NCT06193915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided hematoma block.
Description: Patients with a dislocated fracture of the distal radius will receive ultrasound guided hematoma block with 10mL lidocaine 2% to get real-time guidance of the given anesthesia into the fracture site before closed reduction of a distal radius fracture.
Study NCT06193915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blind hematoma block
Description: Patients with a distal radius fracture will receive standard treatment; hematoma block with 10mL 2% lidocaine performed with palpation of the fracture site (blind hematoma block) before closed reduction of dislocated distal radius fractures.
Study NCT04885218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209 ;placebo
Description: SHR-1209 and placebo 150 mg subcutaneous injection once every 4 weeks for 48 weeks
Study NCT04885218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209 ;placebo
Description: SHR-1209 and placebo 300 mg subcutaneous injection once every 8 weeks for 48 weeks
Study NCT04885218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209 ;placebo
Description: SHR-1209 and placebo 450 mg subcutaneous injection once every 12 weeks for 48 weeks
Study NCT04941833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Desogestrel Oral Tablet
Description: Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel
Study NCT04941833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel Oral Tablet
Description: Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel
Study NCT05530499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond supplementation
Description: Daily consumption of 57g of whole almonds
Study NCT05530499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cookie supplementation
Description: Daily consumption of cookie snack calorically equivalent to 57 grams of whole almonds.
Study NCT06246669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Walking
Description: A treadmill will be used for participant to walk on. The frequency of exercise will be 5 times per week until they report symptom-free. The intensity will be determined via random group allocation (RPE of 13 or 9). The type of exercise is treadmill walking. The time of the intervention will depend on the the time it takes an individual to reach a specific caloric expenditure as a function of their weight and treadmill incline. This is based on the most recent American Congress of Sports Medicine's guidelines for estimating gross energy expenditure during common physical activities.
Study NCT05403944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Rehabilitation (SOC)
Description: 6 weeks of standard of care rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
Study NCT05403944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training Rehabilitation Incorporating Power Exercises (STRIPE)
Description: 6 weeks of STRIPE rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
Study NCT05346887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Therapy
Description: The 18-week caregiver-delivered intervention involves daily 30-minute home-practice and weekly sessions with a therapist over video call or in-person at a local rehabilitation centre. During weekly sessions, the therapist will coach the caregiver(s), problem-solving with them and supporting their autonomy as agents of change in their child's care. The first 13-weeks of the program will be exclusively constraint-induced movement therapy, with bimanual therapy introduced in the last five weeks depending on child age. Intervention content will be individualized based on child age, ability, and interests.
Study NCT05156671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adrecizumab (HAM 8101)
Description: Drip infusion over 60 minutes.
Study NCT05156671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drip infusion over 60 minutes
Study NCT05515341 — intervention group
Intervention type: DEVICE
Intervention: Commercially Approved Interventional Medical Device/Therapy for Chronic Pain
Description: Commercially Approved Interventional Medical Device/Therapy
Study NCT04985916 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical liniment without investigational product
Study NCT04985916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: ET-01 topical liniment
Study NCT04963517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: 8 weeks personalized, multi-modal exercise with focus on lower extremity
Study NCT04963517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: * Initial consultation with recommendations for general physical activity~* Brochure with exercise recommendations.
Study NCT06540794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP TITRATION
Description: Determining the optimal PEEP value that provides the lowest driving pressure using decremental PEEP titration.
Study NCT05817513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release.
Description: Myofascial release (MFR) is a therapeutic treatment that uses gentle pressure and stretching to facilitate the release of fascial restrictions caused by accidents, injury, stress, repetitive use, and traumatic or surgical scarring. The fascial restrictions are palpated by the practitioner and the techniques are applied directly to the skin of the patient without lotions or oils. The pressure is applied into the direction of the restriction just until resistance is felt or the tissue is perceived to stop moving. The pressure is sustained at this point of resistance, without sliding over the skin or forcing the tissue, for a minimum of 90-120s. As the tissue begins to release, the practitioner maintains the same amount of pressure and follows the release three dimensionally through multiple releases.
Study NCT05817513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercises for scoliosis treatment.
Description: The exercises are:~1. Pelvic tilt.~2. Arm and leg raises.~3. Cat-cow.~4. Bird dog.~5. Latismus dorsi stretch.~6. Abdominal press.~7. Practice a good posture.~8. Stretching and scapular exercises.
Study NCT06217627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secretome
Description: The secretome is the secretions of MSCs or explants from umbilical cord tissues. It contains diverse trophic molecules including cytokines, chemokines, angiogenic factors, and growth factors.
Study NCT05158504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivation
Description: Motivational notifications were sent via SMS message to the nurses in the motivation group (n=30) at 07.00, 12.00 and 16.00 for 21 days.
Study NCT05609838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot water foot bath
Description: A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.
Study NCT06409182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopill
Description: HemoPill® acute capsule (Ovesco Endoscopy, Tuebingen, Germany) is a swallowable, wireless, sensor capsule designed for in vivo detection of liquid blood or hematin. The capsule has integrated optical microsensor for blood detection, by transmitting red and violet light via LEDs. It allows the detection of blood by photometric measuring method, in small volumes or in unprepared digestive tract. The dimensions of the capsules are 7.0mm x 26.3mm. The maximal examination time is 9 hours. The HemoPill® receiver is a portable receiver for displaying and storing measured values from the HemoPill® acute capsule. It allows a real-time, wireless, telemetric data transmission. Once activated, the HemoPill® acute capsule can be swallowed by patients with real-time measurement of HemoPill® Indicator (HI). An HI value in the red range suggests a positive finding - liquid blood or hematin has been detected.
Study NCT04577599 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mobile Low-dose Computed Tomography (LDCT) Screening
Description: Low Dose CT Scan of the Chest
Study NCT06509438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embella (Deoxycholic acid, produced by Espad Pharmed Co.)
Description: 2 milliliters of Embella injectable solution containing 20 milligrams of deoxycholic acid
Study NCT05144269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal exercises
Description: Telehabilitation including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises
Study NCT06175845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraductal biliary radiofrequency ablation
Description: Radiofrequency ablation via catheter and transpapillary access of malignant bile duct obstruction
Study NCT05796401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive reinforcement using digital applications (PSYCARE application) during 12 weeks~+/- virtual reality based cognitive remediation application : 24 sessions over 12 weeks (only for patients who have a higher cognitive deficits (TMTB score >110s))
Study NCT05796401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC
Description: Personalised neuroprotective medication adapted to the individual's biological profile :~* Vitamin B12 : 500 micrograms per day~* Folinic acid : 50 mg per day~* Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day~* N-acetyl-cysteine (NAC) : 2400 mg per day~duration of supplementation(s) : 12 weeks
Study NCT05796401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Treatment as usual (TAU), including a standardised psycho-education program with a group cognitive behavioural therapy (e.g. I_Care - You Care) and, in FEP only, second generation antipsychotic from a restricted list (following the recommendations www.orygen.org.au)
Study NCT05796401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Treatment as usual (TAU), including a standardised psycho-education program with a group cognitive behavioural therapy (e.g. I_Care - You Care) and, in FEP only, second generation antipsychotic from a restricted list (following the recommendations www.orygen.org.au)
Study NCT06220929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin
Description: The drug Mecobalamin in the intervention group was divided into intravenous and oral formulations, with the intravenous formulation being used for the first 14 days of the experiment and the oral formulation for the second 14 days.
Study NCT06289218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interferential current
Description: IFC plus exercise
Study NCT06289218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping
Description: KT plus exercise
Study NCT06289218 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: exercise only
Study NCT06220929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone Sodium
Description: Ceftriaxone sodium all intravenous formulations
Study NCT06220929 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: The saline used in the control group was the same as the saline used in the experimental group to dispense the drug
Study NCT06220929 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo and Mecobalamin tablets look and smell the same.
Study NCT06519578 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: hepatic artery infusion chemotherapy
Description: HAIC is a regional therapy that takes advantage of the fact that hepatic tumors, particularly hepatocellular carcinoma, predominantly receive their blood supply from the hepatic artery. The procedure typically involves the insertion of a catheter into the hepatic artery, often through a percutaneous approach or during a surgical procedure.~FOLFOX (5-fluorouracil, leucovorin combined with oxaliplatin) or RALOX (raltitrexed combined with oxaliplatin) Q3W.
Study NCT05425290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-session emotion regulation training
Description: The single-session emotion regulation skills training will blend psychotherapeutic approaches that emphasize effective ER. First, participants will be taught to adopt a detached (i.e., 'distanced') and nonjudgmental attitude towards an emotional situation. Detachment, or 'distancing' as it will be introduced to participants, will be taught by examining the situation with objectivity or putting spatial or temporal distance between the current moment and the situation. Second, research participants will be taught reframing. Specifically, they will be introduced to the relationship between thoughts and emotions and how to find interpretations that are less upsetting in order to be more effective when upset. Participants will identify elements of a situation that they did not pay attention to or information that was missing, and to reframe their thoughts based on the full picture. The emotion regulation training is expected to take approximately 30-45 minutes.
Study NCT03977922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet group
Description: The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
Study NCT05477849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
Description: 1. Dose level 1~2. Dose level 2~3. Dose level 3~4. Dose level 4~5. Dose level 5
Study NCT06091826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFL-101
Description: Subcutaneous injections
Study NCT06091826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections
Study NCT05642091 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound Elastography
Description: application of shear wave force by ultrasound elastography
Study NCT05227534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OverC multi-cancer detection blood test
Description: Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
Study NCT05273515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality and 3D Reconstruction
Description: Using virtual reality and 3D reconstruction to produce personalise images of what participants may look like after 15% and 25% total weight loss.
Study NCT06248866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy
Description: The affected hand or fingers will be positioned comfortably to ensure optimal access to the fibromatosis lesion. Gel or oil will be applied to the skin to enhance the transmission of shock waves. Shock wave therapy will be administered using the selected energy level and frequency settings. Energy level and frequency will be customized based on individual patient requirements. (1000-1500 shock/session, frequency between 5-12HZ, compression power of 1.5- 2.5 bars).and will receive traditional treatment
Study NCT06248866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional treatment
Description: the patients will receive traditional treatment in the form of laser (A low-level laser device with a wavelength of 830 nm and power output of 50 mW will be used as one Of the pain relief methods), ultrasound (An ultrasound device with a frequency of 1 MHz and an intensity of 1.5 W/cm² will be used), stretching and strengthening exercise and splinting.
Study NCT06248866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatment
Description: the patients will receive traditional treatment in the form of laser (A low-level laser device with a wavelength of 830 nm and power output of 50 mW will be used as one Of the pain relief methods), ultrasound (An ultrasound device with a frequency of 1 MHz and an intensity of 1.5 W/cm² will be used), stretching and strengthening exercise and splinting.
Study NCT04871451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-450
Description: ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Study NCT04826042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization
Study NCT04826042 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization
Study NCT06177938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactose solution/Glucose solution
Description: Single ingestion of a lactose/glucose solution.
Study NCT06177938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactose solution/Glucose solution
Description: Single ingestion of a lactose/glucose solution.
Study NCT04896229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talk STEM Familia Treatment Condition
Description: This study has one intervention and two arms: experimental and treatment as usual. Participants randomized to the treatment condition will receive the TSF technology in addition to the vocabulary instruction, monitoring, or resources delivered by English Language Development programs (ELD) and schools. TSF will deliver frequent, brief, dual-language exercises to help families learn, practice and apply SAV words in conversation. Audio-visual lessons will support learning at all literacy levels, regardless of prior familiarity with STEM subjects. The complete TSF tool will contain approximately 72 minutes of video modeling and 12 hours of interactive exercises delivered over 24-weeks in brief, interactive, easy to assimilate lessons.